Saturday 17 October 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow VBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 31.49 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 7.91 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (1.91) | |
P/B ratio |
— | — | — | 0.68 | |
Price to Tangible BV |
— | — | — | 1.14 | |
EV/Sales |
— | — | — | 1.26 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (0.10) | |
EV/FCF |
— | — | — | (0.10) | |
Quick Ratio |
0.69 | 2.76 | 19.57 | 5.44 | |
Current Ratio |
1.11 | 3.31 | 20.13 | 5.86 | |
Net Debt/EBITDA |
(0.99) | 0.06 | 2.93 | 1.39 | |
Debt/Assets |
22.75% | 18.05% | 20.42% | 0.00% | |
Debt/Equity |
0.62 | 0.37 | 0.27 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.10 | |
Operating CF/Net income |
0.72 | 0.78 | 0.76 | 0.77 | |
Capex/Depreciation |
(0.05) | (0.01) | (0.25) | 0.00 | |
Interest Coverage |
(9.30) | (8.69) | (15.73) | 620.75 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 587.67% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,013.70% | |
Intangible Assets out of Total Assets |
0.18 | 0.15 | 0.18 | 0.36 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 95.21% | |
Graham Net Nets |
— | — | — | 0.81 | |
Graham Number |
— | — | — | 73.94 | |
Earnings Yield |
— | — | — | 3.18% | |
Free Cash Flow Yield |
— | — | — | (159.64%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 2.77 | |
Operating CF per Share |
(39.06) | (43.46) | (49.50) | (37.80) | |
Capex per Share |
(0.42) | (0.06) | (0.54) | (0.19) | |
Free Cash Flow per Share |
(39.48) | (43.52) | (50.04) | (37.99) | |
Cash per Share |
15.59 | 62.58 | 273.70 | 65.34 | |
Shareholders Equity per Share |
87.91 | 160.87 | 523.10 | 105.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
87.91 | 160.87 | 523.10 | 105.89 | |
Free Cash Flow |
(5.34) | (5.02) | (2.31) | (2.01) | |
Working Capital |
0.34 | 6.04 | 12.36 | 3.10 | |
Capital Expenditures |
(0.06) | (0.01) | (0.02) | (0.01) | |
Net Current Asset Value |
(17.21) | (11.01) | 5.57 | 3.10 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.07 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.01 | |
Average Payables |
0.44 | 0.53 | 0.19 | 0.40 | |
Average Inventory |
0.53 | 0.53 | — | 0.37 | |
Average Assets |
18.49 | 21.00 | 17.21 | 4.81 | |
Average Common Equity |
3.97 | 7.05 | 9.67 | 4.21 |
Columns are period end dates